Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR3S9B)

• Drug Name: Tyloxapol Drug Info
• Synonyms: Alevaire; Enuclene; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol

Indication

Disease Entry	ICD 11	Status	REF
Congenital alveolar dysplasia		Approved	[1]
Cystic fibrosis	CA25	Terminated	[2]

• Cross-matching ID:
  PubChem CID: 71388
  ChEBI ID: CHEBI:141517
  CAS Number: CAS 25301-02-4
  TTD Drug ID: DMR3S9B

Molecule-Related Drug Atlas

Drug(s) Targeting Nuclear factor NF-kappa-B (NFKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[4]
Triptolide	DMCMDVR	Autoimmune diabetes	5A10	Phase 3	[5]
Laquinimod	DM3IWS8	Lupus	4A40	Phase 3	[6]
Edasalonexent	DMYVBF6	Duchenne dystrophy	8C70	Phase 3	[7]
MD1003	DMVZ57G	Multiple sclerosis	8A40	Phase 3	[7]
Vadimezan	DMK7CYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
CAT 1004	DMQBP7R	Duchenne dystrophy	8C70	Phase 2	[9]
Parthenolide	DMCQBFT	N. A.	N. A.	Phase 2	[10]
Recoflavone	DMCSR8I	Inflammatory bowel disease	DD72	Phase 2	[11]
CZEN-002	DMUDMHA	Fungal infection	1F29-1F2F	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Inhibitor	[3]

References

• [1] Tyloxapol FDA Label
• [2] Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. American Journal of Respiratory and Critical Care Medicine. 10/1996; 154(3 Pt 1):783-8.
• [3] Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6.
• [4] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [5] Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
• [6] Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Auckland Cancer Society Research Centre report
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
• [11] DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
• [12] US patent application no. US20100278784 A1.